Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
Articolo
Data di Pubblicazione:
2013
Abstract:
To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2), against primary USC harboring HER2/neu gene amplification and/or PIK3CA mutations.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
GDC-0980; HER2/neu; PIK3CA; endometrial neoplasms; mTOR inhibitor; uterine serous tumors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bicyclo Compounds, Heterocyclic; Carcinoma, Papillary; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Amplification; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Pyrimidines; TOR Serine-Threonine Kinases
Elenco autori:
English, Diana P; Bellone, Stefania; Cocco, Emiliano; Bortolomai, Ileana; Pecorelli, Sergio; Lopez, Salvatore; Silasi, Dan Arin; Schwartz, Peter E; Rutherford, Thomas; Santin, Alessandro D.
Link alla scheda completa:
Pubblicato in: